The retrospective observational study of clinical outcomes of single dose infusion of warm blood cardioplegia in patients undergoing cardiac surgery

Objective: The aim of the study was to assess the safety and efficacy of a normothermic cardioplegia solution N trademark use and obtain additional information about dosing regimens during normothermic or mild hypothermic cardiac surgery. Methods: A retrospective observational study included 150 cardio surgery patients. The primary endpoint was the intraoperative acute heart failure development. The secondary endpoints were the postoperative Troponin T concentrations, the need for catecholamine support, and the repeated infusion of a cardioplegia solution. Results: The duration of aortic cross-clamping varied from 17 to 154 minutes, median 59 [interquartile range, 46 - 73] minutes. Spontaneous sinus rhythm recovery was observed in 136 (90.7%) patients. Intraoperative acute heart failure was observed in 1 case. The Troponin T concentrations were 0.331 plus-or-minus sign 0.143 ng/mL after surgery. Mortality was 2% (3 patients). Eight patients received an additional volume of N trademark solution to maintain asystole. Among 16 patients with a cross-clamp duration greater than 90 minutes epinephrine was used in 3 (18.8%) patients in doses of more than 0.05 mcg/kg/min. Among 134 patients cross-clamp duration less than 90 minutes the catecholamine support was used in 4 (3%) patients, p=0.027. Conclusions: A primary single-dose infusion of cardioplegia solution N trademark provides myocardial protection for 59 (interquartile range, 46-73) minutes and up to 154 minutes. The catecholamine support in the group of aortic cross-clamp duration less than 90 minutes was used lesser than in the group of aortic cross-clamp duration greater than 90 minutes (3% and 18.8%, respectively). The cardioprotection during cardiopulmonary bypass surgery especially in elderly patients with concomitant disease needs to be confirmed in future investigations.


| INTRODUCTION
The main goal in cardiac surgery since the 1980s was the reduction of the number of intraoperative and postoperative complications. Aortic clamping during cardiopulmonary bypass (CPB) may lead to ischemia-reperfusion injury which is the main cause of complications and mortality in cardiac surgery. It is understood that myocardial failure due to inadequate protection may occur despite surgical success. Perioperative myocardial infarction is one of the most important adverse events occurring during cardiac surgery. [1][2][3][4][5][6] During myocardial ischemia, cardioplegia is the preferred method of myocardial protection.
However, decades after its implementation, there is still no consensus on the optimal redosing interval. Shorter re-dosing (15-30 min) has been preferred to longer intervals (45-60 min), but the choice of one approach over another relies more on the surgeon's preference than on scientific reports. 7 In 2016 the normothermic cardioplegic blood composition N TM , which is explored in this article, was approved for medical use. Recently, a clinical trial was conducted to compare Normacor (N TM ) and Custodiol (Histidine-tryptophan-ketoglutarate). Similar safety and tolerability were demonstrated of both solutions. 8 The mechanism of action of the N TM solution is based on the composition of electrolytes, the main of which is potassium. An influx of potassium depolarizes the myocardial membrane causing contraction and thus release and subsequent sequestration of calcium ions resulting in a diastolic arrest. The persistence of potassium reduces the membrane potential . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 19, 2021. ; https://doi.org/10.1101/2021.07.15.21260424 doi: medRxiv preprint and does not allow for adequate repolarization. As the solution diffuses and there is a washout of its components along with products of cellular metabolism, electrical activity begins to appear, and re-dosing of cardioplegia is required if clinically indicated. Potassium, however, is not the only ion in cardioplegia. Other ions such as magnesium, and mannitol all participate in reducing contractility and preserving the myocardium. 9 N TM protects cardiomyocytes from interstitial edema with mannitol and prevents cellular acidosis with an alkaline pH of the solution. The combination of these factors provides prevention of cellular metabolism disorders.
The upper limit of the duration of aortic clamping and the duration of myocardial protection has not yet been determined due to the limited duration of the operation. To date more than 5000 operations using N™ have been performed in Russia.
The aim of the study was to assess the safety and potential risk of intraoperative acute heart failure (AHF) developing, analyze the efficacy of N™ use and obtain additional information about dosing regimens. The study included all patients, regardless of the severity of heart disease, various concomitant diseases, overweight and the complexity of surgical intervention. The study protocol did not contain exclusion criteria.

| Participants and procedure
The primary endpoint was the intraoperative AHF development, which was identified as a reduced left ventricle ejection fraction (LVEF) <40% after weaning from the CPB and heart rhythm restoration. The secondary endpoints were the postoperative Troponin T concentrations (6 hours after surgery), the need for catecholamine support and repeated infusion of a cardioplegia solution.
Electrocardiography (ECG) and echocardiography were monitored the day before surgery, during surgery, and 6 hours after surgery.
The anesthetic technique consisted of oral premedication (20 mg phenazepam), induction with 2 mg/kg propofol followed by total intravenous anesthesia with propofol (3 mg/kg/ h). The fentanyl 3 mcg/kg/h (continuous intravenous infusion) was used for analgesia. Neuromuscular blockade was achieved by administering pancuronium bromide (0.15 mg/kg) or vecuronium (0.15 mg/kg). Intravenous heparin (300 IU/kg) was administered immediately before cannulation for CPB and additional doses were given to maintain an activated clotting time of 480 s or greater. Mechanical ventilation was carried out using Primus (Drager, Germany), at a tidal volume of 6 ml/kg with 5 cm H2O positive end-expiratory pressure, and at a respiratory rate of 12/min. The radial artery was cannulated with catheter Arteriofix 20G (BBraun, Germany) for continuous blood pressure monitoring (Siemens-7000, Germany). A temperature sensor was placed into the oesophagus. The ECG (the ST segment abnormalities, arrhythmia episodes), and pulsoxymetry were analyzed with a multifunctional monitor . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 19, 2021. ; https://doi.org/10.1101/2021.07.15.21260424 doi: medRxiv preprint (Siemens-7000, Germany). Echocardiography (Esaote MyLab, Italy) was performed during surgery to monitor the left and right ventricular ejection fraction. Blood analysis of arterial and venous blood for electrolyte balance, acid-base balance and gas balance were performed on Stat Profile ССХ (Nova Biomedical, USA) at the beginning and every 30 min of the operation.

| Cardioplegia Protocol
N™ cardioplegic solution was mixed with patient's oxygenated blood. Normothermic cardioplegia was performed by antegrade method through aortic root or coronary arteries separately, or by retrograde method through coronary sinus depending on a type of pathology. The cardioplegic solution was delivered to the aortic root using a roller pump and a tube system as part of CPB (Figure 1).
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 19, 2021. ; https://doi.org/10.1101/2021.07.15.21260424 doi: medRxiv preprint The cardioplegic mixture completely entered into the cardiotomic reservoir. The main criterion for the correct dose of N™ and the indicator of the cardioplegic efficacy was the time until the onset of asystole. In case of antegrade perfusion if the heart has continued to beat after 1 or 2 minutes from the cardioplegia beginning the surgeon checked the aorta cross-clamp and the aortic valve insufficiency. If the solution does not enter the coronary bed in sufficient volume we switched to a retrograde perfusion method. Antegrade perfusion of the cardioplegic mixture of N™ and oxygenated blood was performed in 1:2 ratio. The hematocrit was 23±3. The infusion rate of the mixture according to the antegrade method was 300 ml/min. A total volume of 400 ml of N ™ solution was injected.
Retrograde perfusion of the cardioplegic mixture of N™ and oxygenated blood was performed in 1:2 ratio. The infusion rate of the mixture through the coronary sinus after applying a cross-clamp to the aorta was 100-150 ml/min (pressure didn't exceed 50 mm Hg).
If ventricular activity appeared at the main stage of the operation we maintained asystole by perfusion of the N ™ cardioplegic mixture with oxygenated blood in a ratio of 1:2 using one of the following methods: -Antegrade method with the infusion rate of N™ cardioplegic mixture 150 ml/min until asystole was achieved; -Retrograde method at the infusion rate of N™ cardioplegic mixture of 100-150 ml/ min until the asystole was achieved.
The appearance of atrial activity during the main stage of the operation did not affect the efficacy of myocardial protection.
The effect of cardioplegia was finished immediately after the cross-clamping of aorta was removed. In this case the restoration of cardiac activity occurred mainly through brady-. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 19, 2021.

| Statistical analysis
Data processing and comparison of variables have been performed by appropriate statistical methods. Comparison by qualitative characteristics was performed by the Fischer's exact test, difference between groups was considered significant if p-value was <0.05. Continuous data were checked for normality with D'Agostino-Pearson omnibus normality test.
Comparison between groups was performed using Unpaired T test in case of normal distribution and Mann-Whitney test otherwise. Data analyses were performed using GraphPad Prism 5 (GraphPad Software Inc., CA, USA).

| Patients population
The group of 150 adult patients (60 [52.75 -66.25] years old, male 84 (56%)) was observed. The youngest patient was 22 years old and the oldest one was 80 years old. Body . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 19, 2021.

| Preoperative Diagnosis
The study included 2 (1.3%) patients with a very low ejection fraction of the left ventricle (lesser than 30% according to Simpson J.S.); 26 (17.3%) patients who had myocardial infarction at least 6 months before surgery; 6 (9%) patients had post infarction left ventricular aneurysm. The baseline characteristics of the patients are presented in Table 1 and Figure 2A.

| Type of surgical intervention
The types of surgery are shown in Table 2. Operations for acquired heart defects were performed in 131 (87.3%) patients. Congenital heart disease in 19 (12.7%) patients. Out of them, combined surgical procedures with tricuspid valve repair were performed in 65 (43.3%) patients, and coronary artery bypass graft surgery were performed in 51 (34%) patients. Correction of aorta pathology was performed in 25 (16.7%) cases.

| Intraoperative period
CPB time in 150 surgical procedures ranged from 28 to 274 minutes (Table 3). In 90 (60%) patients the CPB time was less than 90 minutes. In 60 (40%) cases the CPB time was more than 90 minutes, including 25 (16.7%) cases of more than 120 minutes.
The aortic cross-clamp duration varied from 17 to 154 minutes, Figure 2B. The cardiac ischemia time was lesser then 60 minutes in 81 (54%) patients. Long surgical procedures with a cross-clamp duration of more than 120 minutes were performed in 4 (2.7%) patients.
Two patients who had a long period of cross-clamping did not need additional N™ infusion to maintain asystole. Spontaneous sinus rhythm recovery was observed in all 4 cases of long . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 19, 2021. This was either due to incomplete aortic cross-clamping or incomplete closure of the aortic valve due to valve defects.
The N™ solution provided cardioprotection for the entire period necessary to complete the surgery. Undesirable reactions in the application of N™ solution were not detected.

| Clinical outcomes
The myocardium activity recovery time was 95±11 seconds. In other patients sinus rhythm restored after ventricular fibrillation and defibrillation procedure.
In all 150 surgical procedures cardiac arrest type was asystole. Spontaneous sinus rhythm recovery was observed in 136 (90.7%) cases, including 2 patients with LVEF lesser . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 19, 2021. ; https://doi.org/10.1101/2021.07.15.21260424 doi: medRxiv preprint than 30%. Both patients with LVEF lesser than 30% did not require epinephrine support in a dose exceeding 0.05 mcg/kg/min. No arrhythmia was recorded.
Intraoperative AHF occurred in 3 cases. All of them had LVEF more than 55% before surgery. In first two cases multiple organ failure developed after the surgery. In last case a cardiovascular insufficiency developed. This patient received exrtacorporal membrane oxygenation for a ten days and died on 34th day. No cases of stroke, renal, hepatic, pulmonary failure were reported (Table 5).
Defibrillation was performed in 14 (9.3%) patients after aorta declamping. Arrhythmia was recorded in 11 cases (7.3%), 10 of them had LVEF more than 55%. Intraoperative catecholamine support with the epinephrine at a dose of more than 0.05 mcg/kg/min was required in 7 (4.7%) patients (all of them had the LVEF more than 45%). The median ICU length of stay was 22 hours, only 16 (10.7%) patients spent more than 72 hours in the ICU ( Table 5). The ICU length of stay did not statistically significant differ in the groups with short and long cross-clamp duration. This indicates effective heart protection with the N™ solution for any duration of cross-clamping (p=0.679). The length of . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

| Laboratory Parameters
Analysis of laboratory data of arterial and venous blood for electrolyte balance, acid-base balance and gas balance indicates physiological changes during the operation, with the exception of the concentration of potassium ions at the main and final stages of the operation (according to the N TM mechanism of action). All of the above mentioned parameters returned to normal as soon as the operation completed (Figures 3-6).

| Clinical case
As a clinical case we present one patient with a cross-clamp duration of 154 minutes, where additional infusion of the N™ solution was not required. Patient P. underwent the following surgery: replacement of the ascending aorta and aortic valve. The 400 ml of the cardioplegic solution was used to protect the heart in a ratio of 1 part of cardioplegic solution and 2 parts of the oxygenated blood. The duration of infusion was 5 minutes. Cardiac arrest occurred at a first minute. Sinus rhythm recovered within four minutes after the aorta crossclamp was removed. Ventricular activity was not restored during the entire period of crossclamping. Subsequent infusion of N™ to maintain asystole was not required. The patient was weaned from the CPB with the first attempt. Arrhythmia was not noted. No intraoperative complications were observed. The patient was transferred to the ICU without catecholamine support.

| DISCUSSION
Three (2%) patients developed perioperative AHF. Similar 30-day mortality rates (from 1% to 4%) have been reported in other large cardiac surgery studies. [11][12][13] . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 19, 2021. (2018) demonstrated that the safe interval for infusion of normothermic blood cardioplegia was 13 minutes. 15 Ghazy T. et al. (2009) indicated that "the standard in the literature is still the repeated infusion of cardioplegic blood solution every 15 minutes". 16 Molina GR et al. (2018) noted that once cross-clamp is applied, and infusion of cold blood cardioplegia has begun, typical ECG changes can be observed in one to two minutes time and an isoelectric ECG recording is obtained after 3 to 4 minutes that lasts for at least 90 minutes or longer. Unless aortic clamping failure occurs, repeated doses of cardioplegia are not required. Other aspects of myocardial protection should be observed such as preventing left ventricle overdistension and avoiding rewarming of the heart. Continuous topical cooling with iced saline solution or slush is advisable. 17  Subsequent infusion of the solution was necessary due to incomplete infusion of the entire volume of mixture at the beginning of the main stage of the operation due to incomplete aorta cross-clamping or incomplete aortic valve closure. It was never necessary to infuse a repeated dose of N™ more than once to maintain asystole even if the duration of the cross-clamp exceeds 120 minutes.
Our analysis has several limitations. This is a single center report. The study was neither comparative nor randomized. This study does not elucidate a clear mechanism of action for N TM solution. We does not provide data regarding the N-terminal pro-brain natriuretic peptide as a marker of myocardial injury. The inclusion of patients with comorbidities in separate groups could add a confounding variable in the study. This study is limited in the dura-. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 19, 2021. ; https://doi.org/10.1101/2021.07.15.21260424 doi: medRxiv preprint tion of followup within 1 month. This work represents a pilot clinical study of acute heart failure development and catecholamine support and requires confirmation by large clinical studies to verify the efficacy of cardioplegia based on N TM solution in clinical settings involving ischemia-reperfusion injury.

| CONCLUSIONS
Normothermic blood cardioplegia solution N™ can be used both for standard cardiac Acknowledgements: The authors thank «Federal Center for Cardiovascular Surgery» of Astrakhan for assistance with this work.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 19, 2021. ; https://doi.org/10.1101/2021.07.15.21260424 doi: medRxiv preprint  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 19, 2021.     . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 19, 2021.  is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 19, 2021. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted July 19, 2021.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 19, 2021. ; https://doi.org/10.1101/2021.07.15.21260424 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 19, 2021. ; https://doi.org/10.1101/2021.07.15.21260424 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 19, 2021. ; https://doi.org/10.1101/2021.07.15.21260424 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 19, 2021. ; https://doi.org/10.1101/2021.07.15.21260424 doi: medRxiv preprint Figure 6. Hematocrit in arterial (red dots) and venous (blue dots) blood of the patients. Black line represent median values. Dash lines represents the normal range of the parameter. Each dot represents one patient.
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted July 19, 2021. ; https://doi.org/10.1101/2021.07.15.21260424 doi: medRxiv preprint